KS BioMedix: an alternative route to the marketplace

Published By Datamonitor

Monoclonal antibodies: sales to increase six-fold by 2005

Published By Datamonitor

Colorectal cancer: sales to top $1 billion by 2007

Published By Datamonitor

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor

Cancer: launch of angiogenesis inhibitors will increase treatment options

Published By Datamonitor

Cytotoxic antibiotics: sales down 4% by 2007

Published By Datamonitor

Inex/GSK: the growing importance of drug delivery

GSK will foot the bill for Inex's development work. In a market where drug delivery is becoming as important as the compound itself, the deal represents a good chance for GSK to boost the sales and life expectancy of its drug. Inex, meanwhile, should gain significant opportunities by partnering with a leading pharmaceutical company.

Published By Datamonitor

Prostate cancer: UK lowest for screening

Published By Datamonitor

GW Pharma: more cannabis spray trials

GW is in a unique position. Although cannabis use is illegal in the UK, the company has the right to grow the drug for use in clinical trials. If the latest trials are successful, up to 40% of cancer patients may be able to benefit from the therapy. Strong trial results would leave GW in a position to gain approval for its product as early as 2004.

Published By Datamonitor

Lung cancer: non small cell most common in major markets

Published By Datamonitor